Close Menu
Subscribe
South Africa

South Africa regulator reviews 12 generic semaglutide applications

Ghana NewsBy No Comments1 Min Read
Scientific model of the molecule semaglutide which is the active ingredient in Novo Nordisk’s mega-blockbuster diabetes drug Ozempic and weight-loss drug Wegovy sits in the office of Mads Krogsgaard Thomsen in Hellerup, Denmark, October 3, 2023. REUTERS/Ali Withers/File Photo

JOHANNESBURG, July 21 (Reuters) – South Africa’s health regulator is reviewing 12 applications for generic versions of semaglutide, the active ingredient in Novo Nordisk’s blockbuster diabetes and weight-loss medicines, it said on Tuesday.

Share.

Related Posts

Leave A Reply